-
Studies of selected patients with ischemic cardiomyopathy have shown improved survival with the use of prophylactic implantable cardioverter
defibrillators (ICD). Thus, DEFibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) was designed to test the survival benefit of ICDs in patients with heart failure but without coronary artery disease.
-
The efficacy and safety study of oral direct thrombin Inhibitor Ximelagatran Compared with Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) was presented by Dr. Jonathan Halperin.
-
In this study, Blackshear and colleagues report on their experience with thoracoscopic surgical techniques to close the left atrial appendage as prophylaxis against stroke in patients with atrial fibrillation.
-
In this report, Higgins and colleagues report on a multicenter trial on the efficacy of cardiac resynchronization therapy in patients with an indication for an implantable cardioverter defibrillator.
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
-
In a multicenter study of occupational HIV exposures, 38% of source patients had genotype mutations associated with resistance to antiretroviral drugs. Recent antiretroviral treatment history was highly associated with resistance.
-
The results of genetic analysis of a strain of S aureus with high-level resistance to vancomycin suggest that this resistance was the consequence of genetic transfer from a VRE to an MRSA, each present in and on the unfortunate patient who served as the incubator.
-
-
St Johns Wort and Drug Interactions; Serum Potassium and Stroke Risk Among Hypertensive Adults; Skin Cancer Prevention and Detection Practices Among Siblings of Patients with Melanoma, TZDs and HF in People with Type 2 Diabetes; Exercise Plus Behavioral Management in Patients with AD; Spironolactone in Resistant HBP
-
Blood pressure reduction in the first 24 hours of stroke onset is independently associated with poor outcome after 3 months.